Last $117.32 USD
Change Today -2.99 / -2.49%
Volume 3.6M
CELG On Other Exchanges
As of 11:31 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

celgene corp (CELG) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/23/15 - $125.45
52 Week Low
04/15/14 - $66.85
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELGENE CORP (CELG)

celgene corp (CELG) Related Businessweek News

View More BusinessWeek News

celgene corp (CELG) Details

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML). The company’s products also include THALOMID for the patients with multiple myeloma and for the treatment of cutaneous manifestations of erythema nodosum leprosum; OTEZLA for psoriatic arthritis, psoriasis, and ankylosing spondylitis; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its clinical stage products comprise oral anti-inflammatory agents targeting PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486 to treat MDS, AML, and solid tumors; Sotatercept and luspatercept for the treatment of anemia; and CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; MorphoSys AG; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; and NantBioScience, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

6,012 Employees
Last Reported Date: 02/20/15
Founded in 1980

celgene corp (CELG) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.3M
President and Chief Operating Officer
Total Annual Compensation: $666.7K
Chief Executive Officer of Celgene Cellular T...
Total Annual Compensation: $645.8K
President of Global Hematology and Oncology
Total Annual Compensation: $753.3K
President of Research & Early Development an...
Total Annual Compensation: $645.8K
Compensation as of Fiscal Year 2013.

celgene corp (CELG) Key Developments

FDA Expands Indication for Celgene's REVLIMID® (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID® (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma (NDMM). REVLIMID plus dexamethasone was previously approved in June 2006 for use in multiple myeloma patients who have received at least one prior therapy. The approval of REVLIMID as an option for use in all patients with multiple myeloma represents a new paradigm in the management of this disease. The approval was based on safety and efficacy results from phase III studies, including the FIRST trial (MM-020/IFM 07-01), which evaluated continuous REVLIMID in combination with dexamethasone (Rd Continuous) until disease progression versus melphalan, prednisone and thalidomide (MPT) for 18 months as the primary analysis, and a fixed duration of 18 cycles of Rd (Rd18) as a secondary analysis, in 1,623 newly diagnosed patients who were not candidates for stem cell transplant. In this randomized, open-label, three-arm trial, median progression-free survival (PFS), the length of time a patient lives from study randomization to disease progression or death was the primary endpoint of the study. PFS was significantly longer for patients receiving Rd Continuous (25.5 months) than for those treated with MPT (21.2 months; HR=0.72; p=0.0001). Median overall survival (OS) in the two groups was 58.9 months and 48.5 months, respectively (HR 0.75; 95% CI 0.62, 0.90) based on a March 3, 2014 interim OS analysis. Patients in the Rd Continuous arm had a 25% reduction in the risk of death compared to patients in the MPT arm. Safety results showed that adverse reactions reported in â ¥20% of NDMM patients in the Rd Continuous, Rd18 or MPT arms included diarrhea (45.5%, 38.5%, 16.5%), anemia (43.8%, 35.7%, 42.3%), neutropenia (35.0%, 33.0%, 60.6%), fatigue (32.5%, 32.8%, 28.5%), back pain (32.0%, 26.9%, 21.4%), insomnia (27.6%, 23.5%, 9.8%), asthenia (28.2%, 22.8%, 22.9%), rash (26.1%, 28.0%, 19.4%), decreased appetite (23.1%, 21.3%, 13.3%), cough (22.7%, 17.4%, 12.6%), pyrexia (21.4%, 18.9%, 14.0%), muscle spasms (20.5%, 18.9%, 11.3%) and abdominal pain (20.5%, 14.4%, 11.1%).

Celgene Corporation Reports Earnings Results for the Fourth Quarter and Full Year of 2014; Provides Earnings Guidance for the Year 2015; Provides Earnings Guidance for the Periods beyond 2015

Celgene Corporation reported earnings results for the fourth quarter and full year of 2014. In the fourth quarter, earnings growth was largely driven by operating income with a modest benefit from a lower tax rate and share count. GAAP net income was USD 2.0 billion for the quarter, up 37.9%, with USD 2.39 diluted earnings per share. Product sales grew 19% year over year to USD 2.06 billion and adjusted EPS grew 24% year over year. In the fourth quarter, net product sales growth was indeed primarily driven by volume. The volatility in the foreign exchange markets toward the end of the year drove approximately a USD 25 million fourth quarter unfavorable impact to total net product sales, resulting in a negative 1.4% point impact to growth. Full year, earnings growth was also high quality, based largely on operating income, which accounted for USD 0.71 of the USD 0.73 per share increase year-over-year. The gains from the improved tax rate and the favorable cumulative impact of share repurchase program were offset by increased financial expenses associated with May 2014 USD 2.5 billion debt offering and hedging program. Adjusted earnings per share growth accelerated in both the fourth quarter and full year compared to 2013. 2014 revenues were up 18% year on year to USD 7.67 billion. The growth was boosted by the strong performance of Revlimid(lenalidomide), having increased 16% y/y to USD 4.98 billion in 2014, as a result of rises in therapy duration and market share. Focusing on 2015, the company expected total net product sales between USD 9.0 billion and USD 9.5 billion, up 22.3% year on year by the mid-point range in 2015, as sales of Revlimid are anticipated to rise 13.5% at the mid-way range to USD 5.6 to USD 5.7 billion. Adjusted diluted EPS are forecasted in the range of USD 4.60 to USD 4.75, up 26% year on year, while GAAP EPS are anticipated to range between USD 3.68 and USD 3.92. Beyond 2015, Celgene has also presented it’s long-term financial targets, anticipating products' sales ranging between USD 13.0 billion and USD 14.0 billion in 2017, with Revlimid's sales reaching USD 7.0 billion. By 2020, Celgene forecasts products' sales will exceed USD 20.0 billion, led by it’s haematology franchise, which is valued at approximately USD 14.8 billion. Adjusted EPS target is to achieve over USD 12.50 per share, which represents a 23% compound annual growth rate from 2014 to 2020.

Celgene Corporation Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 09:30 AM

Celgene Corporation Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 09:30 AM. Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: George Golumbeski, SVP, Business Development.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CELG:US $117.35 USD -2.96

CELG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $59.94 USD -0.52
Amgen Inc $158.39 USD -1.24
Astellas Pharma Inc ¥1,977 JPY +27.00
Bristol-Myers Squibb Co $61.70 USD -0.60
Regeneron Pharmaceuticals Inc $409.81 USD -8.63
View Industry Companies

Industry Analysis


Industry Average

Valuation CELG Industry Range
Price/Earnings 50.8x
Price/Sales 12.7x
Price/Book 14.9x
Price/Cash Flow 43.1x
TEV/Sales 10.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at